{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:44:13Z","timestamp":1789055053100,"version":"build-2803163510"},"reference-count":86,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Hypertension remains a significant health burden worldwide, re-emphasizing the outstanding need for more effective and safer antihypertensive therapeutic approaches. Genetic variation contributes significantly to interindividual variability in treatment response and adverse events, suggesting pharmacogenomics as a major approach to optimize such therapy. This review examines the molecular mechanisms underlying antihypertensives-associated adverse events and surveys existing research on pharmacogenomic biomarkers associated with these events. The current literature revealed limited conclusive evidence supporting the use of genetic variants as reliable indicators of antihypertensive adverse events. However, several noteworthy associations have emerged, such as 1) the role of <jats:italic>ACE<\/jats:italic> variants in increasing the risk of multiple adverse events, 2) the bradykinin pathway\u2019s involvement in cough induced by ACE inhibitors, and 3) the impact of <jats:italic>CYP2D6<\/jats:italic> variants on metoprolol-induced bradycardia. Nonetheless, challenges persist in identifying biomarkers for adverse events across different antihypertensive classes, sometimes due to the rarity of certain events, such as ACE inhibitors-induced angioedema. We also highlight the main limitations of previous studies that warrant attention, including using a targeted gene approach with a limited number of tested variants, small sample sizes, and design issues such as overlooking doses or the time between starting treatment and the onset of adverse events. Addressing these challenges requires collaborative efforts and the integration of technological advancements, such as next-generation sequencing, which can significantly enhance research outcomes and provide the needed evidence. Furthermore, the potential combination of genomic biomarker identification and machine learning is a promising approach for tailoring antihypertensive therapy to individual patients, thereby mitigating the risk of developing adverse events. In conclusion, a deeper understanding of the mechanisms and the pharmacogenomics of adverse events in antihypertensive therapy will likely pave the way for more personalized treatment strategies to improve patient outcomes.<\/jats:p>","DOI":"10.3389\/fphar.2023.1286494","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T17:59:50Z","timestamp":1701453590000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Antihypertensives associated adverse events: a review of mechanisms and pharmacogenomic biomarkers available evidence in multi-ethnic populations"],"prefix":"10.3389","volume":"14","author":[{"given":"Sahar M.","family":"Altoum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeina N.","family":"Al-Mahayri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassam R.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,12,1]]},"reference":[{"key":"B1","article-title":"Thiazide diuretics","volume-title":"StatPearls","author":"Akbari","year":"2022"},{"key":"B2","doi-asserted-by":"publisher","first-page":"35685","DOI":"10.1074\/jbc.M110.167866","article-title":"The N domain of human angiotensin-I-converting enzyme: the role of N-glycosylation and the crystal structure in complex with an N domain-specific phosphinic inhibitor, RXP407","volume":"285","author":"Anthony","year":"2010","journal-title":"J. Biol. Chem."},{"key":"B3","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/j.1365-2125.2009.03567.x","article-title":"Potential genetic risk factors in angiotensin-converting enzyme-inhibitor-induced angio-oedema","volume":"69","author":"Bas","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.1365-2125.2008.03325.x","article-title":"A common NOS1AP genetic polymorphism is associated with increased cardiovascular mortality in users of dihydropyridine calcium channel blockers","volume":"67","author":"Becker","year":"2009","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"4629419","DOI":"10.1155\/2022\/4629419","article-title":"Multiomics integrated analysis identifies SLC24A2 as a potential link between type 2 diabetes and cancer","volume":"2022","author":"Bian","year":"2022","journal-title":"J. Diabetes Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/clpt.2008.172","article-title":"Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users","volume":"85","author":"Bijl","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/cts.12692","article-title":"Standardizing CYP2D6 genotype to phenotype translation: consensus recommendations from the clinical pharmacogenetics implementation Consortium and Dutch pharmacogenetics working group","volume":"13","author":"Caudle","year":"2020","journal-title":"Clin. Transl. Sci."},{"key":"B8","first-page":"142","article-title":"Impact of ABO rs505922 genetic variant on angiotensin-converting enzyme activity in Thai population","volume":"20","author":"Chaikan","year":"2020","journal-title":"Sci. Technol. Asia"},{"key":"B9","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/cts.12389","article-title":"Melatonin pathway and atenolol\u2010related glucose dysregulation: is there a correlation?","volume":"9","author":"Chang","year":"2016","journal-title":"Clin. Transl. Sci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/tpj.2016.67","article-title":"Genome-wide association study identifies pharmacogenomic loci linked with specific antihypertensive drug treatment and new-onset diabetes","volume":"18","author":"Chang","year":"2018","journal-title":"Pharmacogenomics J."},{"key":"B11","doi-asserted-by":"publisher","first-page":"665250","DOI":"10.3389\/fphar.2021.665250","article-title":"The impact of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers on clinical outcomes of acute kidney disease patients: a systematic review and meta-analysis","volume":"12","author":"Chen","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1002\/humu.21579","article-title":"A functional XPNPEP2 promoter haplotype leads to reduced plasma aminopeptidase P and increased risk of ACE inhibitor-induced angioedema","volume":"32","author":"Cilia La Corte","year":"2011","journal-title":"Hum. Mutat."},{"key":"B13","doi-asserted-by":"publisher","first-page":"416","DOI":"10.3390\/jpm13030416","article-title":"Metoprolol and CYP2D6: a retrospective cohort study evaluating genotype-based outcomes","volume":"13","author":"Collett","year":"2023","journal-title":"J. Personalized Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1161\/CIRCGENETICS.113.000421","article-title":"Is a diabetes-linked amino acid signature associated with beta blocker-induced impaired fasting glucose?","volume":"7","author":"Cooper-DeHoff","year":"2014","journal-title":"Circ. Cardiovasc Genet."},{"key":"B15","unstructured":"Cpicpgx2023"},{"key":"B16","article-title":"Metoprolol therapy and CYP2D6 genotype","volume-title":"Medical genetics summaries","author":"Dean","year":"2012"},{"key":"B17","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/j.1751-7176.2010.00386.x","article-title":"Hypertension, dyslipidemia, and insulin resistance in patients with diabetes mellitus or the cardiometabolic syndrome: benefits of vasodilating \u03b2-blockers","volume":"13","author":"Deedwania","year":"2011","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/tpj.2013.3","article-title":"Genome-wide association analyses suggest NELL1 influences adverse metabolic response to HCTZ in African Americans","volume":"14","author":"Del-Aguila","year":"2014","journal-title":"Pharmacogenomics J."},{"key":"B19","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/tpj.2014.46","article-title":"Transethnic meta-analysis suggests genetic variation in the HEME pathway influences potassium response in patients treated with hydrochlorothiazide","volume":"15","author":"Del-Aguila","year":"2015","journal-title":"Pharmacogenomics J."},{"key":"B20","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/s41397-019-0132-y","article-title":"Genome-wide meta-analysis of variant-by-diuretic interactions as modulators of lipid traits in persons of European and African ancestry","volume":"20","author":"de Las Fuentes","year":"2020","journal-title":"Pharmacogenomics J."},{"key":"B21","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s11306-016-1076-8","article-title":"Novel plasma biomarker of atenolol-induced hyperglycemia identified through a metabolomics-genomics integrative approach","volume":"12","author":"de Oliveira","year":"2016","journal-title":"Metabolomics"},{"key":"B22","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/sj.jhh.1000856","article-title":"Does Chinese ethnicity affect the pharmacokinetics and pharmacodynamics of angiotensin-converting enzyme inhibitors?","volume":"14","author":"Ding","year":"2000","journal-title":"J. Hum. Hypertens."},{"key":"B23","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1086\/496899","article-title":"A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors","volume":"77","author":"Duan","year":"2005","journal-title":"Am. J. Hum. Genet."},{"key":"B24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/23808993.2018.1420419","article-title":"Pharmacogenomic studies of hypertension: paving the way for personalized antihypertensive treatment","volume":"3","author":"Eadon","year":"2018","journal-title":"Expert Rev. Precis. Med. Drug Dev."},{"key":"B25","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1161\/HYPERTENSIONAHA.109.129171","article-title":"Thiazide effects and adverse effects: insights from molecular genetics","volume":"54","author":"Ellison","year":"2009","journal-title":"Hypertension"},{"key":"B26","unstructured":"Escardio2023"},{"key":"B27","article-title":"Beta blockers","volume-title":"StatPearls","author":"Farzam","year":"2022"},{"key":"B28","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.tcm.2019.05.003","article-title":"Blood pressure and the new ACC\/AHA hypertension guidelines","volume":"30","author":"Flack","year":"2020","journal-title":"Trends Cardiovasc. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s10557-017-6733-2","article-title":"The pharmacogenomic and metabolomic predictors of ACE inhibitor and angiotensin II receptor blocker effectiveness and safety","volume":"31","author":"Flaten","year":"2017","journal-title":"Cardiovasc Drugs Ther."},{"key":"B30","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.celrep.2016.05.092","article-title":"Decreased consumption of branched-chain amino acids improves metabolic health","volume":"16","author":"Fontana","year":"2016","journal-title":"Cell. Rep."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1161\/01.HYP.35.5.1025","article-title":"Hypokalemia associated with diuretic use and cardiovascular events in the systolic hypertension in the elderly program","volume":"35","author":"Franse","year":"2000","journal-title":"Hypertension"},{"key":"B32","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1177\/1470320313510583","article-title":"Influence of ABO genotype and phenotype on angiotensin-converting enzyme plasma activity","volume":"15","author":"Gass\u00f3","year":"2014","journal-title":"J. Renin Angiotensin Aldosterone Syst."},{"key":"B33","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/phar.1355","article-title":"PROX1 gene variant is associated with fasting glucose change after antihypertensive treatment","volume":"34","author":"Gong","year":"2014","journal-title":"Pharmacotherapy"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1210\/jc.2015-3964","article-title":"Thiazide-associated hypercalcemia: incidence and association with primary hyperparathyroidism over two decades","volume":"101","author":"Griebeler","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B35","unstructured":"American College of Cardiology2022"},{"key":"B36","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1157\/13124715","article-title":"The role of ace gene polymorphism in the development of angioedema secondary to angiotensin converting enzyme inhibitors and angiotensin II receptor blockers","volume":"36","author":"Gulec","year":"2008","journal-title":"Allergol. Immunopathol. Madr."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1161\/HYPERTENSIONAHA.116.08729","article-title":"Risk factors for nonadherence to antihypertensive treatment","volume":"69","author":"Gupta","year":"2017","journal-title":"Hypertension"},{"key":"B38","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2217\/pgs-2016-0184","article-title":"Genetic variants associated with angiotensin-converting enzyme inhibitor-induced cough: a genome-wide association study in a Swedish population","volume":"18","author":"Hallberg","year":"2017","journal-title":"Pharmacogenomics"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.2147\/PPA.S368784","article-title":"A critical review of medication adherence in hypertension: barriers and facilitators clinicians should consider","volume":"16","author":"Hamrahian","year":"2022","journal-title":"Patient Prefer Adherence"},{"key":"B40","article-title":"Angiotensin II receptor blockers (ARB)","volume-title":"StatPearls","author":"Hill","year":"2022"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e001521","DOI":"10.1161\/JAHA.115.001778","article-title":"Pharmacogenomics of hypertension: a genome\u2010wide, placebo\u2010controlled cross\u2010over study, using four classes of antihypertensive drugs","volume":"4","author":"Hiltunen","year":"2015","journal-title":"J. Am. Heart Assoc."},{"key":"B42","unstructured":"WHO2023"},{"key":"B43","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/sj.tpj.6500324","article-title":"beta-Blockade and increased dyslipidemia in patients bearing Glu27 variant of beta2 adrenergic receptor gene","volume":"5","author":"Iaccarino","year":"2005","journal-title":"Pharmacogenomics J."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1097\/HJH.0b013e32833c7a4d","article-title":"Pharmacogenetic association of hypertension candidate genes with fasting glucose in the GenHAT Study","volume":"28","author":"Irvin","year":"2010","journal-title":"J. Hypertens."},{"key":"B45","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1159\/000106554","article-title":"Beta-2-adrenergic receptor polymorphisms and changes in lipids induced by metoprolol","volume":"80","author":"Isaza","year":"2007","journal-title":"Pharmacology"},{"key":"B46","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.bbrc.2011.06.111","article-title":"A new function of nell-1 protein in repressing adipogenic differentiation","volume":"411","author":"James","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B47","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/hr.2014.8","article-title":"Chapter 5 Treatment with antihypertensive drugs","volume":"37","year":"2014","journal-title":"Hypertens. Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/tpj.2012.34","article-title":"Association of KCNJ1 variation with change in fasting glucose and new onset diabetes during HCTZ treatment","volume":"13","author":"Karnes","year":"2013","journal-title":"Pharmacogenomics J."},{"key":"B49","doi-asserted-by":"publisher","first-page":"3465929","DOI":"10.1155\/2018\/3465929","article-title":"A review on adducin from functional to pathological mechanisms: future direction in cancer","volume":"2018","author":"Kiang","year":"2018","journal-title":"Biomed. Res. Int."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.3390\/life12111891","article-title":"Altered serum uric acid levels in kidney disorders","volume":"12","author":"Kim","year":"2022","journal-title":"Life"},{"key":"B51","doi-asserted-by":"publisher","first-page":"e2200580","DOI":"10.1200\/PO.22.00580","article-title":"Polygenic pharmacogenomic markers as predictors of toxicity phenotypes in the treatment of acute lymphoblastic leukemia: a single-center study","volume":"7","author":"Larkin","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"e026582","DOI":"10.1161\/JAHA.122.026582","article-title":"Global burden, regional differences, trends, and health consequences of medication nonadherence for hypertension during 2010 to 2020: a meta\u2010analysis involving 27 million patients","volume":"11","author":"Lee","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"B53","doi-asserted-by":"publisher","first-page":"e0281460","DOI":"10.1371\/journal.pone.0281460","article-title":"Impact of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers on clinical outcomes in hypertensive patients with acute myocardial infarction","volume":"18","author":"Lee","year":"2023","journal-title":"PLoS One"},{"key":"B54","doi-asserted-by":"publisher","first-page":"e37396","DOI":"10.1371\/journal.pone.0037396","article-title":"Angiotensin-converting enzyme (ACE) gene insertion\/deletion polymorphism and ACE inhibitor-related cough: a meta-analysis","volume":"7","author":"Li","year":"2012","journal-title":"PLoS One"},{"key":"B55","doi-asserted-by":"publisher","first-page":"2209336","DOI":"10.1080\/07853890.2023.2209336","article-title":"Machine learning algorithms identify hypokalaemia risk in people with hypertension in the United States National Health and Nutrition Examination Survey 1999\u20132018","volume":"55","author":"Lin","year":"2023","journal-title":"Ann. Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1097\/FPC.0000000000000050","article-title":"Rs495828 polymorphism of the ABO gene is a predictor of enalapril-induced cough in Chinese patients with essential hypertension","volume":"24","author":"Luo","year":"2014","journal-title":"Pharmacogenet Genomics"},{"key":"B57","doi-asserted-by":"publisher","first-page":"17253","DOI":"10.1038\/srep17253","article-title":"SLCO1B1 variants and angiotensin converting enzyme inhibitor (Enalapril)-Induced cough: a pharmacogenetic study","volume":"5","author":"Luo","year":"2015","journal-title":"Sci. Rep."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/cpt.1927","article-title":"Exome sequencing reveals common and rare variants in F5 associated with ACE inhibitor and angiotensin receptor blocker-induced angioedema","volume":"108","author":"Maroteau","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"B59","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1097\/FPC.0b013e328348c6db","article-title":"Pharmacogenetic predictors of angiotensin-converting enzyme inhibitor-induced cough: the role of ACE, ABO, and BDKRB2 genes","volume":"21","author":"Mas","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"B60","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/cpt.2355","article-title":"Adverse cardiovascular outcomes and antihypertensive treatment: a genome-wide interaction meta-analysis in the international Consortium for antihypertensive pharmacogenomics studies","volume":"110","author":"McDonough","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"B61","article-title":"Calcium Channel blockers","volume-title":"StatPearls","author":"McKeever","year":"2022"},{"key":"B62","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/ckj\/sfac198","article-title":"Thiazide diuretics are back in CKD: the case of chlorthalidone","volume":"16","author":"Minutolo","year":"2022","journal-title":"Clin. Kidney J."},{"key":"B63","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/jch.12104","article-title":"Association of B2 receptor polymorphisms and ACE activity with ACE inhibitor-induced angioedema in black and mixed-race South Africans","volume":"15","author":"Moholisa","year":"2013","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"B64","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1515\/hmbci-2019-0036","article-title":"A new prospective on the role of melatonin in diabetes and its complications","volume":"40","author":"Mok","year":"2019","journal-title":"Horm. Mol. Biol. Clin. Investig."},{"key":"B65","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/tpj.2015.51","article-title":"A genome-wide association study identifies variants in KCNIP4 associated with ACE inhibitor-induced cough","volume":"16","author":"Mosley","year":"2016","journal-title":"Pharmacogenomics J."},{"key":"B66","doi-asserted-by":"publisher","first-page":"189","DOI":"10.2217\/pgs-2018-0157","article-title":"Association between genetic polymorphisms and angiotensin-converting enzyme inhibitor-induced cough: a systematic review and meta-analysis","volume":"20","author":"Mu","year":"2019","journal-title":"Pharmacogenomics"},{"key":"B67","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1161\/01.hyp.36.1.127","article-title":"Bradykinin B(2) receptor gene polymorphism is associated with angiotensin-converting enzyme inhibitor-related cough","volume":"36","author":"Mukae","year":"2000","journal-title":"Hypertension"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1172\/JCI24134","article-title":"Enhanced passive Ca2+ reabsorption and reduced Mg2+ channel abundance explains thiazide-induced hypocalciuria and hypomagnesemia","volume":"115","author":"Nijenhuis","year":"2005","journal-title":"J. Clin. Invest."},{"key":"B69","doi-asserted-by":"publisher","first-page":"977","DOI":"10.2165\/00003495-200262070-00001","article-title":"Angiotensin converting enzyme gene insertion\/deletion polymorphism and cardiovascular disease: therapeutic implications","volume":"62","author":"Niu","year":"2002","journal-title":"Drugs"},{"key":"B70","doi-asserted-by":"publisher","first-page":"341","DOI":"10.2147\/PGPM.S230201","article-title":"Pharmacogenomics and hypertension: current insights","volume":"12","author":"Oliveira-Paula","year":"2019","journal-title":"PGPM"},{"key":"B71","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1097\/FPC.0b013e328363c137","article-title":"Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema","volume":"23","author":"Pare","year":"2013","journal-title":"Pharmacogenet Genomics"},{"key":"B72","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2217\/pgs-2019-0134","article-title":"Pharmacogenomics at the center of precision medicine: challenges and perspective in an era of Big Data","volume":"21","author":"Primorac","year":"2020","journal-title":"Pharmacogenomics"},{"key":"B73","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/s41397-020-0165-2","article-title":"Genome-wide association study of angioedema induced by angiotensin-converting enzyme inhibitor and angiotensin receptor blocker treatment","volume":"20","author":"Rasmussen","year":"2020","journal-title":"Pharmacogenomics J."},{"key":"B74","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/j.1524-6175.2004.03789.x","article-title":"Diuretic-related side effects: development and treatment","volume":"6","author":"Sica","year":"2004","journal-title":"J. Clin. Hypertens."},{"key":"B75","doi-asserted-by":"publisher","first-page":"e007339","DOI":"10.1161\/JAHA.117.007339","article-title":"Genome wide association study identifies the HMGCS2 locus to be associated with chlorthalidone induced glucose increase in hypertensive patients","volume":"7","author":"Singh","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"B76","doi-asserted-by":"publisher","first-page":"47087","DOI":"10.1074\/jbc.M107165200","article-title":"Short term effect of aldosterone on Na,K-ATPase cell surface expression in kidney collecting duct cells","volume":"276","author":"Summa","year":"2001","journal-title":"J. Biol. Chem."},{"key":"B77","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/B978-0-12-801238-3.65408-9","article-title":"Calcium Channel blockers","volume-title":"Encyclopedia of endocrine diseases","author":"Taddei","year":"2019"},{"key":"B78","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2174\/1874192401105010085","article-title":"Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases","volume":"5","author":"Tziomalos","year":"2011","journal-title":"Open Cardiovasc Med. J."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","article-title":"2020 international society of hypertension global hypertension practice guidelines","volume":"75","author":"Unger","year":"2020","journal-title":"Hypertension"},{"key":"B80","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/joim.12215","article-title":"Hydrochlorothiazide-induced hyperuricaemia in the pharmacogenomic evaluation of antihypertensive responses study","volume":"276","author":"Vandell","year":"2014","journal-title":"J. Intern Med."},{"key":"B81","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.ophtha.2023.05.001","article-title":"Association of systemic medication use with glaucoma and intraocular pressure: the European eye epidemiology Consortium","volume":"130","author":"Vergroesen","year":"2023","journal-title":"Ophthalmology"},{"key":"B82","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00228-005-0081-z","article-title":"Hydrochlorothiazide efficacy and polymorphisms in ACE, ADD1 and GNB3 in healthy, male volunteers","volume":"62","author":"Vormfelde","year":"2006","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1097\/FPC.0b013e32833d3acb","article-title":"Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema","volume":"20","author":"Woodard-Grice","year":"2010","journal-title":"Pharmacogenet Genomics"},{"key":"B84","doi-asserted-by":"publisher","first-page":"648","DOI":"10.2337\/dc12-0895","article-title":"Branched-chain and aromatic amino acids are predictors of insulin resistance in young adults","volume":"36","author":"W\u00fcrtz","year":"2013","journal-title":"Diabetes Care"},{"key":"B85","doi-asserted-by":"publisher","first-page":"635","DOI":"10.21037\/cdt-22-154","article-title":"Personalized antihypertensive treatment guided by pharmacogenomics in China","volume":"12","author":"Xiao","year":"2022","journal-title":"Cardiovasc Diagn Ther."},{"key":"B86","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41392-023-01619-w","article-title":"Drug-microbiota interactions: an emerging priority for precision medicine","volume":"8","author":"Zhao","year":"2023","journal-title":"Sig Transduct. Target Ther."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1286494\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T17:59:57Z","timestamp":1701453597000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1286494\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":86,"alternative-id":["10.3389\/fphar.2023.1286494"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1286494","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,1]]},"article-number":"1286494"}}